Treasury Secretary Scott Bessent expressed on Monday that the trade agreement achieved over the weekend signifies a further step in the U.S. reducing its dependence on Chinese products.
Although the U.S. has been contemplating “decoupling” from its reliance on inexpensive imports from China for years, the progress has been gradual and a complete separation seems improbable.
Nevertheless, Bessent stated that there are now specific decoupling strategies in place that are crucial to U.S. interests. In 2024, the U.S. imported nearly $440 billion worth of goods from China, resulting in a trade deficit of $295.4 billion.
“We do not desire a blanket decoupling from China,” he remarked during an interview on CNBC’s “Squawk Box.” “However, what we are seeking is a decoupling in areas of strategic necessity, which we could not secure during the Covid pandemic, leading to the realization that efficient supply chains are not necessarily resilient ones.”
When the pandemic hit in 2020, the U.S. demand shifted from services to a greater emphasis on goods. This resulted in increased challenges in sourcing materials for various products, including major appliances and vehicles. The technology sector, heavily reliant on semiconductors, was also affected. This shift contributed to an inflation surge in the U.S. not seen in over four decades.
The details of the U.S.-China pact remain unclear, but U.S. officials have indicated that the so-called reciprocal tariffs will be suspended, although the broad 10% duties will stay in place.
“We are going to produce our own steel. [Tariffs] safeguard our steel industry. They are critical for essential medicines and semiconductors,” Bessent noted. “We are proceeding with this, and the reciprocal tariffs are unrelated to specific-industry tariffs.”
The agreement between the two nations essentially provides a 90-day pause where reciprocal duties will be suspended, yet the 10% tariff along with a 20% charge concerning fentanyl will persist.
Bessent showed optimism on the fentanyl issue, noting that Chinese officials “are now earnest in aiding the U.S. to halt the flow of precursor drugs.” Bessent did not specify an exact date for the next round of discussions but suggested it should occur in the upcoming weeks.
